WO2006032009A3 - Methods for prediction and prognosis of cancer, and monitoring cancer therapy - Google Patents

Methods for prediction and prognosis of cancer, and monitoring cancer therapy Download PDF

Info

Publication number
WO2006032009A3
WO2006032009A3 PCT/US2005/033095 US2005033095W WO2006032009A3 WO 2006032009 A3 WO2006032009 A3 WO 2006032009A3 US 2005033095 W US2005033095 W US 2005033095W WO 2006032009 A3 WO2006032009 A3 WO 2006032009A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
prognosis
prediction
methods
monitoring
Prior art date
Application number
PCT/US2005/033095
Other languages
French (fr)
Other versions
WO2006032009A2 (en
Inventor
Douglas Bigwood
Original Assignee
Bayer Pharmaceuticals Corp
Douglas Bigwood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Douglas Bigwood filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006032009A2 publication Critical patent/WO2006032009A2/en
Publication of WO2006032009A3 publication Critical patent/WO2006032009A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of cortactin as a biomarker for kinase inhibitors.
PCT/US2005/033095 2004-09-14 2005-09-14 Methods for prediction and prognosis of cancer, and monitoring cancer therapy WO2006032009A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60993604P 2004-09-14 2004-09-14
US60/609,936 2004-09-14

Publications (2)

Publication Number Publication Date
WO2006032009A2 WO2006032009A2 (en) 2006-03-23
WO2006032009A3 true WO2006032009A3 (en) 2006-09-08

Family

ID=36060721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033095 WO2006032009A2 (en) 2004-09-14 2005-09-14 Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Country Status (1)

Country Link
WO (1) WO2006032009A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8983580B2 (en) 2008-01-18 2015-03-17 The Board Of Trustees Of The University Of Illinois Low-coherence interferometry and optical coherence tomography for image-guided surgical treatment of solid tumors

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127526A2 (en) * 2007-03-12 2008-10-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
US20100234381A1 (en) * 2007-04-13 2010-09-16 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIGLARESE M.R. ET AL.: "The protein tyrosine substrate cortactin is differentially expressed in murine B lymphoid tumors", ONCOGENE, vol. 9, 1994, pages 1989 - 1997 *
SCHUURING E.D. ET AL.: "The produce of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is lovated in cell-substratum contact sites", MOLECULAR AND CELLULAR BIOLOGY, vol. 13, no. 5, May 1993 (1993-05-01), pages 2891 - 2898 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8983580B2 (en) 2008-01-18 2015-03-17 The Board Of Trustees Of The University Of Illinois Low-coherence interferometry and optical coherence tomography for image-guided surgical treatment of solid tumors

Also Published As

Publication number Publication date
WO2006032009A2 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2007047955A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007056012A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007056011A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007059094A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2006089125A3 (en) Methods of detecting ovarian cancer
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
IL197450A0 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
IL184900A0 (en) Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2007141280A3 (en) Proteins
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
WO2005080593A8 (en) P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
WO2005009434A3 (en) Compounds and methods for inducing apoptosis in cancer cells
EP2073843A4 (en) Methods of diagnosing, treating, or preventing plasma cell disorders
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
WO2008054598A8 (en) Panel of biomarkers for prediction of fti efficacy
WO2008115710A3 (en) Biomarkers for cancer
WO2006032009A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2004028352A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007118073A3 (en) Obesity and body fat distribution
WO2008026008A8 (en) Protein
WO2008069976A3 (en) Compounds and methods for enzyme-mediated tumor imaging and therapy
WO2009098451A3 (en) Biomarkers of aminopeptidase inhibition
WO2006086859A3 (en) Method and kit to profile tumours by biomarker analyses including transcriptional factor assays

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase